Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$4.90 USD
+0.03 (0.62%)
Updated Aug 6, 2025 09:30 AM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLRB 4.90 +0.03(0.62%)
Will CLRB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLRB
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
CLRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies
4 Medical Product Stocks to Watch From a Challenging Industry
4 Medical Product Stocks to Buy From a Challenging Industry
Other News for CLRB
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Insider Buying: James Caruso Acquires 10,000 Shares of Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Announces Closing of $6. ...
12 Health Care Stocks Moving In Tuesday's Intraday Session
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering | CLRB Stock News